Logo Logo
Hilfe
Hilfe
Switch Language to English

Plett, Helmut; Harter, Philipp; Ataseven, Beyhan; Heitz, Florian; Prader, Sonia; Schneider, Stephanie; Heikaus, Sebastian; Fisseler-Eckhoff, Annette; Kommoss, Friedrich; Lax, Sigurd F.; Staebler, Annette; Traut, Alexander und du Bois, Andreas (2020): Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. In: Gynecologic Oncology, Bd. 157, Nr. 2: S. 411-417

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Background. Borderline ovarian tumors (BOT) are considered a biological category with increased epithelial proliferation and cellular atypia in the absence of invasive growth. Since BOT occur often in young patients fertility sparing surgery (FSS) is an important issue. With this study we aimed to evaluate risk factors for relapses and fertility of patients after FSS. Methods. Patients diagnosed with BOT and treated between 2000 and 2018 were included. External pathological review was done in all patients. FSS was performed after individual discussion and a complete surgical staging according to FIGO, without lymphadenectomy and with a waiver for preservation of uterus and one ovary. Results. Among 352 Patients 80.2% had FIGO I and 63.9% had a serous BOT. Eighteen patients (5.1%) relapsed and 4 cases of malignant transformation were reported (1.1%). One patient of the latter died, all others have no evidence of disease. The overall recurrence-rate was 1.1% in FIGO-Stage I and 25.5% in FIGOII-IV (HR = 27;95%- CI-7.7-95;p <=.001). 95 patients underwent FSS. Thirteen (13.7%) of these patients relapsed, all as BUT. In multi- variate analysis FIGO stages II-IV (HR = 27;95%-CI: 8.1-102;p <=.001) and FSS ( HR = 12: 95%-CI: p <=.001) remained significant risk factors for recurrent disease. Pregnancy rate among forty-one patients attempting to conceive was 82.9%. 29 patients experienced at least one life-birth, in total 38 life-births were reported. Conclusion. FSS in stage I is a safe procedure and life-birth-rates after FSS are high. More advanced FIGO stages have to be discussed individually and relapse rates have to be weighed against FSS. A central review of pathology, as we performed routinely, is mandatory and may have contributed to our low rate of invasive relapses.

Dokument bearbeiten Dokument bearbeiten